See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

The first cohort in the ongoing clinical Phase 2a study EXIST evaluated a lower dose of exidavnemab compared to placebo in patients with Parkinson's disease. An interim safety review showed that ...

Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for b ...

Two new drugs targeting early-stage Alzheimer’s disease are expected to be put into clinical use as soon as Thursday next ...

Part of the law also means that some Alzheimer's patients won't have to go through step therapy, a process of using a less ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $190.82, a high estimate of ...

A new Fujirebio Diagnostics blood test identifies beta-amyloid, a brain plaque that is a key marker for Alzheimer’s disease.

Content by Health System. June is Alzheimer’s and Brain Awareness Month, which means there’s no better time to focus on your brain health.

An alarming number of Canadians—over 414—are diagnosed each day with Alzheimer’s or another form of dementia.¹ By 2050, this could […] ...

NewAmsterdam Pharma has said that an oral drug it is developing to lower cholesterol has shown preliminary efficacy as a ...

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

A Chinese company that developed the country’s first indigenous therapy for Alzheimer’s disease has suspended production and sales of the drug, casting doubts on the treatment’s future.